Comparison

Cycloheximide European Partner

Item no. HY-12320-1g
Manufacturer MedChem Express
Amount 1 g
Category
Type Inhibitors
Specific against other
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias Naramycin A, Actidione
Available
Synonyms
Naramycin A, Actidione
MW
2813474
Solubility
DMSO: >= 33 mg/mL; H2O: 20 mg/mL (Need ultrasonic and warming)
Biological Description
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms, with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.

IC50 & Target: IC50: 532.5 nM (protein synthesis), 2.88 uM (RNA synthesis)[1]
In Vitro: Cycloheximide (CHX) is the most common laboratory reagent used to inhibit protein synthesis. Cycloheximide has been shown to block the elongation phase of eukaryotic translation. Cycloheximide binds the ribosome and inhibits eEF2-mediated translocation. Surprisingly, Cycloheximide allows one complete translocation cycle to proceed before halting any further elongation. Cycloheximide has been speculated that Cycloheximide requires an E-site bound deacylated tRNA for activity[1].
In Vivo: The mice receive Cycloheximide injections at 30, 60, or 120 mg/kg prior to training with a 200 uA shock. There is a significant effect of Cycloheximide on latencies on the memory test trials (P<0.001). In saline controls, this shock level results in latencies on the test trial that are significantly higher than those at training. Injections of the lowest dose of Cycloheximide tested, 30 mg/kg, results in latencies on the test trial that are significantly higher than those seen in the saline control group. Mice receiving either of the two higher doses of Cycloheximide has latencies on the test trial that are comparable to those of the saline group, i.e., the higher doses neither enhanced nor impaired memory under these conditions, resulting in an inverted-U dose-response curve for Cycloheximide enhancement of memory[2]. Infarct volume, as measured by morphometric analysis of infarct areas with triphenyl tetrazolium chloride (TTC), is significantly reduced by 92% and 61% when Cycloheximide is given 0 or 6 hr after HI respectively, but shows an insignificant trend in infarct reduction if Cycloheximide is administered 12 hr after hypoxia-ischemia (HI) compared to the HI control group, and no protective effect is observed when administration is delayed until 24 hr after HI[3].
Publications
Biochim Biophys Acta. 2016 Dec; 1859(12):1527-1537.
Free  Sample
Available in quantities of 0, 5mg-1mg. Three different samples per customer per year!
Journal
Wang H, et al. NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy. Cell Death Dis. 2017 Sep 14; 8(9):e3048.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 g
Available: Out of stock
Questions about this Product?
 
Close